Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

2.920 +0.020 (+0.69%)

Delayed Quote Updated: 11:01 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

10 Biggest Price Target Changes For Friday ↗

July 23, 2021

Keybanc raised the price target on Twitter, Inc. (NYSE: TWTR) from $77 to $81. Twitter shares rose 6.4% to $74.00 in pre-market trading. Baird boosted the price target for...

Via Benzinga

61 Biggest Movers From Yesterday ↗

July 23, 2021

Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares jumped 138.2% to close at $13.22 on Thursday after the company announced new results from its TATX-03 PolyTope Therapy...

Via Benzinga

Mid-Afternoon Market Update: Dow Rises Over 50 Points; ImmunoPrecise Antibodies Shares Spike Higher ↗

July 22, 2021

Toward the end of trading Thursday, the Dow traded up 0.16% to 34,853.89 while the NASDAQ rose 0.38% to 14,687.85. The S&P also rose, gaining 0.20% to 4,367.55. The U.S. has...

Via Benzinga

Topics Stocks

38 Stocks Moving In Thursday's Mid-Day Session ↗

July 22, 2021

Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares climbed 129.7% to $12.75 after the company announced new results from its TATX-03 PolyTope Therapy, demonstrating...

Via Benzinga

Stocks Flat as Nasdaq Tries For 3 Straight ↗

July 22, 2021

A surprise jump in jobless claims is weighing on investor sentiment midday. The Dow Jones Industrial Average is down 34 points, while the S&P 500 Index is trading near breakeven.

Via Talk Markets

Topics Stocks

Mid-Day Market Update: Crude Oil Up 1.5%; Seres Therapeutics Shares Plunge ↗

July 22, 2021

Midway through trading Thursday, the Dow traded down 0.08% to 34,768.64 while the NASDAQ rose 0.10% to 14,646.39. The S&P also fell, dropping 0.02% to 4,357.70. The U.S. has...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 22, 2021

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 53.01% to $15.47 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume...

Via Benzinga

Why Seres Therapeutics Stock Is Crashing Today ↗

July 22, 2021

The company reported disappointing results from a phase 2b clinical study.

Via The Motley Fool

Mid-Morning Market Update: Markets Mostly Lower; AT&T Beats Q2 Estimates ↗

July 22, 2021

Following the market opening Thursday, the Dow traded down 0.24% to 34,715.42 while the NASDAQ rose 0.13% to 14,651.19. The S&P also fell, dropping 0.08% to 4,355.29. The U.S...

Via Benzinga

Topics Stocks

The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO ↗

July 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical...

Via Benzinga

Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis

July 22, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study ↗

July 22, 2021

Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis...

Via Benzinga

Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis

July 22, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases ↗

July 01, 2021

Seres Therapeutics Inc (NASDAQ: MCRB) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109 is an...

Via Benzinga

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

July 01, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Present at JMP Securities Life Sciences Conference

June 10, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Host Virtual Investor Event on June 21, 2021

June 10, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

June 04, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials ↗

June 01, 2021

The FDA has signed off Seres Therapeutics Inc's (NASDAQ: MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial. SER-155 is a...

Via Benzinga

Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)

June 01, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Present at Upcoming Virtual Investor Conferences

May 25, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021

May 21, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development

May 20, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

May 19, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

May 12, 2021

From Seres Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 11, 2021

Gainers Applied DNA Sciences (NASDAQ:APDN) shares rose 27.71% to $7.42 during Tuesday's regular session. Trading volume for Applied DNA Sciences's stock is 7.2...

Via Benzinga

Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting

May 11, 2021

From Seres Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗

May 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Seres Therapeutics: Q1 Earnings Insights ↗

May 04, 2021

Shares of Seres Therapeutics (NASDAQ:MCRB) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 39.29% year over year to ($0...

Via Benzinga

Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

May 04, 2021

From Seres Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.